EU approves Fiasp (rapid acting insulin aspart) for the treatment of diabetes.- Novo Nordisk

Novo Nordisk announced that the European Commission has granted marketing authorisation for Fiasp for the treatment of diabetes in adults. The authorisation covers all 28 European Union member states. Fiasp is the brand name for fast-acting insulin aspart. Fiasp provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid. Fiasp is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals.

The incremental benefits with Fiasp are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago. Fiasp will be available in vial, Penfill and FlexTouch pen. Novo Nordisk expects to launch Fiasp in the first European countries in the first half of 2017.

Fiasp is insulin aspart (NovoRapid ) in a new formulation, in which two new excipients have been added to ensure earlier, greater and faster absorption, thereby providing earlier insulin action. The review of Fiasp was based on the onset programme, a phase III clinical programme comprising of four trials encompassing more than 2,100 people with type 1 and type 2 diabetes.